Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Liver Diseases

  Free Subscription


Articles published in Clin Res Hepatol Gastroenterol

Retrieve available abstracts of 147 articles:
HTML format



Single Articles


    July 2025
  1. SUALEHEEN A, Tan SY, Daly RM, Georgousopoulou E, et al
    Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population.
    Clin Res Hepatol Gastroenterol. 2025;49:102649.
    PubMed     Abstract available


  2. LU Y, Yi F, Chen W, Tan X, et al
    Involvement of oxidative stress, lipid dysmetabolism and gut microbiol dysbiosis in oxaliplatin-induced fatty liver disease: evidence from a tree shrew model.
    Clin Res Hepatol Gastroenterol. 2025;49:102645.
    PubMed     Abstract available


  3. LUCE E, Messina A, Duclos-Vallee JC
    Hepatic organoids as a platform for liver disease modeling and the development of novel therapies.
    Clin Res Hepatol Gastroenterol. 2025;49:102647.
    PubMed     Abstract available


  4. JIANG Y, Huang Y, Hu X, Chen G, et al
    The role of tumor microenvironment in lenvatinib resistance of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102642.
    PubMed     Abstract available


  5. CARRIER P, Chalange M, Girard M, Premaud A, et al
    Liver fibrosis evaluation in patients with psychiatric diseases.
    Clin Res Hepatol Gastroenterol. 2025;49:102636.
    PubMed     Abstract available


  6. LANTHIER N
    Does the benefit of optimal MASH treatment depend on a reduction in myosteatosis?
    Clin Res Hepatol Gastroenterol. 2025;49:102640.
    PubMed     Abstract available


  7. WANG P, Guo G, Jiang S, Ding D, et al
    Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: Assess the causal relationship using the updated RUCAM scale.
    Clin Res Hepatol Gastroenterol. 2025;49:102635.
    PubMed     Abstract available


  8. ZHENG SS, Zhang D, Wu JF, Chen H, et al
    Circulating tumor DNA in peripheral blood may predict the efficacy of immune-targeted therapy in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102632.
    PubMed     Abstract available


  9. XU X, Zhao H, Zhang J, Yan H, et al
    Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations.
    Clin Res Hepatol Gastroenterol. 2025;49:102617.
    PubMed     Abstract available


    June 2025
  10. SAIFI ES, Faita F, Nardin M, Orizio P, et al
    Evaluation of long-term changes in liver function and structure in patients exposed to SARS-CoV-2 infection: A prospective study.
    Clin Res Hepatol Gastroenterol. 2025;49:102606.
    PubMed     Abstract available


  11. BEN YEDDER N, Girot P, Koudougou C, Schnee M, et al
    Lack of prior screening for advanced liver fibrosis in patients with newly diagnosed hepatocellular carcinoma: Results from a prospective multicentre study.
    Clin Res Hepatol Gastroenterol. 2025;49:102607.
    PubMed     Abstract available


  12. ZHANG C, Sun M, Ding Y, Yuan X, et al
    Research progress on the regulatory role of different cell death pathways in metabolic-dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2025;49:102578.
    PubMed     Abstract available


  13. JAIN P, Jain A, Deshmukh R, Samal P, et al
    Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies.
    Clin Res Hepatol Gastroenterol. 2025;49:102584.
    PubMed     Abstract available


    May 2025
  14. LEE CH, Kang MG, Oh S, Gwak IS, et al
    Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study.
    Clin Res Hepatol Gastroenterol. 2025;49:102612.
    PubMed     Abstract available


  15. YANG LL, Chen X, Huang KT, Tang ST, et al
    BEND3 promotes hepatocellular carcinoma progression and metastasis by activating the PI3K/AKT/mTOR pathway and inducing epithelial-mesenchymal transition.
    Clin Res Hepatol Gastroenterol. 2025;49:102582.
    PubMed     Abstract available


  16. VILLAVICENCIO EA, Serdjebi C, Maldonado A, Ochoa Mora E, et al
    Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting.
    Clin Res Hepatol Gastroenterol. 2025;49:102581.
    PubMed     Abstract available


  17. KHALIL SM, de Souza MHG, de Oliveira FD, Sato EDBS, et al
    Efficacy and safety of aldafermin for the treatment of metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2025;49:102579.
    PubMed     Abstract available


    April 2025
  18. LANTHIER N, Spahr L
    Macrophage therapy and liver regeneration: Results and perspectives.
    Clin Res Hepatol Gastroenterol. 2025;49:102569.
    PubMed     Abstract available


  19. YANG T, Wang SY
    Integrating transcriptome and metabolomics analyses of hepatocellular carcinoma to discover novel biomarkers and drug targets.
    Clin Res Hepatol Gastroenterol. 2025;49:102546.
    PubMed     Abstract available


  20. MAHDIZADEH F, Sobhi P, Banaei S
    A class of MicroRNAs as diagnostic biomarkers and therapeutic strategies in non-alcoholic fatty liver disease: A review.
    Clin Res Hepatol Gastroenterol. 2025;49:102547.
    PubMed     Abstract available


    March 2025
  21. LI Y, Ma XM, Jia JG, Cao LY, et al
    Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A Prospective Cohort Study.
    Clin Res Hepatol Gastroenterol. 2025 Mar 15:102573.
    PubMed     Abstract available


  22. HE Y, Ye M, Xia Y, Zhong Z, et al
    The role of cytokines as predictors for NAFLD-related diseases: A bidirectional Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2025;49:102545.
    PubMed     Abstract available


  23. ABDEL MONEM MS, Adel A, Abbassi MM, Abdelaziz DH, et al
    Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.
    Clin Res Hepatol Gastroenterol. 2025;49:102543.
    PubMed     Abstract available


  24. SOUSA A, Al Masad Q, Pena P, Espat NJ, et al
    Impact of immunotherapy on the care patterns and outcomes of patients with advanced hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102542.
    PubMed     Abstract available


  25. BORGNE-SANCHEZ A, Fromenty B
    Mitochondrial dysfunction in drug-induced hepatic steatosis: Recent findings and current concept.
    Clin Res Hepatol Gastroenterol. 2025;49:102529.
    PubMed     Abstract available


    February 2025
  26. LIU Z, Yang X, Jiang H, Xie R, et al
    Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis.
    Clin Res Hepatol Gastroenterol. 2025 Feb 19:102553.
    PubMed     Abstract available


  27. CATURANO A, Erul E
    The impact of incidental hepatocellular carcinoma in liver transplantation: A growing concern.
    Clin Res Hepatol Gastroenterol. 2025;49:102550.
    PubMed     Abstract available


  28. SERDJEBI C, Foucher J, Besson A, Gay J, et al
    Hepatoscope 2DTE's image-based quality index enhances applicability and repeatability of liver stiffness measurement.
    Clin Res Hepatol Gastroenterol. 2025;49:102532.
    PubMed     Abstract available


  29. KUMAR J, Hasan M, Mohsin S, Alzaher MH, et al
    Assessing the efficacy of farnesoid X receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis: Efficacy of Farnesoid X Receptor Agonists in Metabolic Dysfunction-associated
    Clin Res Hepatol Gastroenterol. 2025;49:102530.
    PubMed     Abstract available


  30. SHI R, Hui X, Tong T, Li J, et al
    Non-bioartificial artificial liver support system in acute liver failure: A comprehensive systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2025;49:102527.
    PubMed     Abstract available


  31. QIAO H, Guo H, Liang Z, Kang L, et al
    Primary hepatocellular carcinosarcoma: A case series and literature review.
    Clin Res Hepatol Gastroenterol. 2025;49:102520.
    PubMed     Abstract available


  32. QUINN PL, Tounkara F, Rodriguez MG, Chahal K, et al
    Access to care and the Hispanic paradox among Hispanic patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102519.
    PubMed     Abstract available


    January 2025
  33. XIE JW, Wang HL, Lin LQ, Guo YF, et al
    Telomere-methylation genes: Novel prognostic biomarkers for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2025;49:102516.
    PubMed     Abstract available


  34. SASAKI M, Sato Y, Nakanuma Y
    A heterogeneous subtype of biliary epithelial senescence may be involved in the pathogenesis of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2025;49:102512.
    PubMed     Abstract available


  35. PARANTHAMAN S, Hani U, Osmani RAM, Bhosale RR, et al
    Current advances in nanoparticle-based approaches for the hepatocellular carcinoma treatment.
    Clin Res Hepatol Gastroenterol. 2025;49:102508.
    PubMed     Abstract available


  36. ALLAIRE M, Garcia H, Meyblum L, Mouri S, et al
    Non selective beta-blockers prevent PHT-related complications occurrence in HCC patients with esophageal varices treated by TACE.
    Clin Res Hepatol Gastroenterol. 2025;49:102496.
    PubMed     Abstract available


    December 2024
  37. LV Q, Xiang YC, Qiu YY, Xiang Z, et al
    Safety and efficacy of the enhanced recovery after surgery protocol in hepatectomy for liver cancer.
    Clin Res Hepatol Gastroenterol. 2024;48:102493.
    PubMed     Abstract available


  38. TORIGUCHI K, Hatano E, Sudo M, Nakamura I, et al
    Intra- and inter-patient diversity in hepatocellular carcinoma based on phosphorylation profiles-A pilot study in a single institution.
    Clin Res Hepatol Gastroenterol. 2024;48:102497.
    PubMed     Abstract available


  39. BUSSO C, Nault JC, Layese R, Demory A, et al
    Prolonged survival in women with hepatocellular carcinoma: A French observational study.
    Clin Res Hepatol Gastroenterol. 2024;48:102498.
    PubMed     Abstract available


  40. ZHANG L, Dang N, Wang J, Zhang W, et al
    ZNF143-mediated upregulation of MEX3C promotes hepatocellular carcinoma progression.
    Clin Res Hepatol Gastroenterol. 2024;48:102492.
    PubMed     Abstract available


  41. CHEN Y, Zhao H, Wang Y, Liu B, et al
    The clinical prognostic risk stratification system for HIV infected hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102479.
    PubMed     Abstract available


    November 2024
  42. WANG Z, Wang Z, Li F, Cai J, et al
    Construction and Validation of a Machine Learning-Based Prediction Model for Short-Term Mortality in Critically Ill Patients with Liver Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 30:102507.
    PubMed     Abstract available


  43. ZHANG Y, Li P, Chen B, Zheng R, et al
    Therapeutic effects of fecal microbial transplantation on alcoholic liver injury in rat models.
    Clin Res Hepatol Gastroenterol. 2024;48:102478.
    PubMed     Abstract available


  44. WU H, Yan W, Liu K, Jing J, et al
    Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury.
    Clin Res Hepatol Gastroenterol. 2024;48:102472.
    PubMed     Abstract available


  45. LEE YP, Chiu CC, Chang YC, Chen YH, et al
    Co-exposure to different bacterial species' lipopolysaccharides with the NASH diet exacerbates NASH and liver fibrosis progression in mice.
    Clin Res Hepatol Gastroenterol. 2024;48:102470.
    PubMed     Abstract available


  46. LIU L, He W, Liu J
    Camrelizumab combined with transcatheter arterial chemoembolization for intermediate or advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102465.
    PubMed     Abstract available


  47. JIANG J, Bouquet E, Kweon Y, Elsaid MI, et al
    Neighborhood Opportunity is Associated with Completion of Hepatocellular Carcinoma Surveillance Prior to the Diagnosis of Hepatocellular Carcinoma in Patients with Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 1:102485.
    PubMed     Abstract available


    October 2024
  48. ZHONG H, Lu S, Xu M, Liu N, et al
    Predictive value of hepatic venous pressure gradient in cirrhotic portal vein thrombosis development.
    Clin Res Hepatol Gastroenterol. 2024 Oct 29:102484.
    PubMed     Abstract available


  49. COURET A, King JA, Pereira B, Courteix D, et al
    Effect of different modalities of exercise on Fatty Liver Index in patients with metabolic syndrome: The RESOLVE randomized trial.
    Clin Res Hepatol Gastroenterol. 2024;48:102461.
    PubMed     Abstract available


  50. YU T, Luo L, Xue J, Tang W, et al
    Gut microbiota-NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102458.
    PubMed     Abstract available


  51. LEMMENS T, Sebagh M, De Martin E
    DRESS syndrome associated with a hemophagocytic lympho-histiocytosis: A rare presentation of DILI induced by a nutritional supplement.
    Clin Res Hepatol Gastroenterol. 2024;48:102455.
    PubMed    


  52. CANCADO GGL, Fucuta PDS, Gomes NMF, Couto CA, et al
    Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102453.
    PubMed     Abstract available


  53. ZHAO B, Xue J, Zhang H
    Causal effects of smoking, alcohol consumption, and coffee intake on hepatobiliary and pancreatic diseases: A Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102450.
    PubMed     Abstract available


  54. HUANG Y, Zeng J, Liu T, Xu Q, et al
    ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism.
    Clin Res Hepatol Gastroenterol. 2024;48:102446.
    PubMed     Abstract available


  55. WANG M, Liu X, Qiao C, Chen R, et al
    Association of congenital hepatic fibrosis and Caroli's syndrome: Two illustrative cases.
    Clin Res Hepatol Gastroenterol. 2024;48:102443.
    PubMed    


  56. GU S, Hu S, Wang S, Shi C, et al
    Altered biliary microbial and metabolic profile reveals the crosstalk between NAFLD and cholelithiasis.
    Clin Res Hepatol Gastroenterol. 2024;48:102431.
    PubMed     Abstract available


  57. LIANG Y
    Mechanisms of sorafenib resistance in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102434.
    PubMed     Abstract available


  58. KUMAR R, Rani M, Ramsha, Kumar V, et al
    Effectiveness of mobile health intervention for non alcoholic fatty liver disease- A meta analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2024;48:102433.
    PubMed     Abstract available


  59. VINAYAGAMOORTHY V, Srivastava A, Anuja AK, Agarwal V, et al
    Biomarker for infection in children with decompensated chronic liver disease: Neutrophilic CD64 or procalcitonin?
    Clin Res Hepatol Gastroenterol. 2024;48:102432.
    PubMed     Abstract available


  60. LIU C, Liu H, Parra MA, Qi L, et al
    Laparoscopic anatomical right hepatectomy using a four-incision anterior approach: Technical details and surgical outcomes (with Video).
    Clin Res Hepatol Gastroenterol. 2024;48:102427.
    PubMed     Abstract available


  61. TAO Y, Cheng C
    Targeting SMOX for the treatment of hepatocellular carcinoma?
    Clin Res Hepatol Gastroenterol. 2024;48:102429.
    PubMed     Abstract available


  62. TAN S
    Molecular mechanism of portal hypertensive gastropathy: An update.
    Clin Res Hepatol Gastroenterol. 2024;48:102423.
    PubMed     Abstract available


  63. YOU Y, Chen S, Deng H, Xing X, et al
    Remifentanil represses oxidative stress to relieve hepatic ischemia/reperfusion injury via regulating BACH1/PRDX1 axis.
    Clin Res Hepatol Gastroenterol. 2024;48:102422.
    PubMed     Abstract available


    September 2024
  64. JIN KM, Bao Q, Zhao TT, Wang HW, et al
    Comparing Baseline VAF in Circulating tumor DNA and Tumor Tissues Predicting Prognosis of Patients with Colorectal Cancer Liver Metastases After Curative Resection.
    Clin Res Hepatol Gastroenterol. 2024 Sep 12:102464.
    PubMed     Abstract available


  65. HAO NB, Zhou Y, Zhang D, Li YN, et al
    Effect of sarcopenia on liver cirrhosis with complicating oesophageal and gastric varices after endoscopic therapy.
    Clin Res Hepatol Gastroenterol. 2024 Sep 10:102459.
    PubMed     Abstract available


  66. KURNIAWAN J, Siahaan BS
    Performance of Spleen Stiffness Measurement by 100-Hz Vibration-Controlled Transient Elastography, Liver Stiffness, APRI Score and their Combination for Predicting Oesophageal Varices in Liver Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Sep 1:102456.
    PubMed     Abstract available


    August 2024
  67. GANTZEL RH, Deleuran T, Vilstrup H, Watson H, et al
    The CIRrhotic Ascites Severity (CIRAS) model predicts hepatic hydrothorax at all stages of ascites.
    Clin Res Hepatol Gastroenterol. 2024;48:102452.
    PubMed     Abstract available


  68. XIANG W, Ni J, Dong L, Zhu G, et al
    ZNF300 promotes proliferation and migration of hepatocellular carcinoma by upregulating c-MYC gene expression.
    Clin Res Hepatol Gastroenterol. 2024;48:102415.
    PubMed     Abstract available


  69. SUNDI PRIO, Thipe VC, Omar MA, Adelusi TI, et al
    Preclinical human and murine models of hepatocellular carcinoma (HCC).
    Clin Res Hepatol Gastroenterol. 2024;48:102418.
    PubMed     Abstract available


  70. EZHILARASAN D, Najimi M
    Quiescent hepatic stellate cell activation in liver fibrosis: Have we found the right trigger yet?
    Clin Res Hepatol Gastroenterol. 2024;48:102420.
    PubMed    


  71. LIN YL, Yao T, Wang YW, Yu JS, et al
    Association between primary biliary cholangitis with diabetes and cardiovascular diseases: A bidirectional multivariable Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102419.
    PubMed     Abstract available


  72. OLIVEIRA HM, Ramos JP, Rego F, Nunes R, et al
    Palliative care and end stage liver disease: A survey study comparing perspectives of hepatology and palliative care physicians and clinical scenarios that could require palliative care intervention.
    Clin Res Hepatol Gastroenterol. 2024;48:102416.
    PubMed     Abstract available


  73. DEMIRCI S, Sezer S, Erdogan K, Abdulsalam AJ, et al
    Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: An observational study with ISarcoPRM algorithm.
    Clin Res Hepatol Gastroenterol. 2024;48:102412.
    PubMed     Abstract available


  74. RONOT M
    Imaging-based assessment of sarcopenia in patients with compensated advanced chronic liver disease: One step further.
    Clin Res Hepatol Gastroenterol. 2024;48:102409.
    PubMed    


  75. MANGOURA SA, Ahmed MA, Hamad N, Zaka AZ, et al
    Vildagliptin ameliorates intrapulmonary vasodilatation and angiogenesis in chronic common bile duct ligation-induced hepatopulmonary syndrome in rat.
    Clin Res Hepatol Gastroenterol. 2024;48:102408.
    PubMed     Abstract available


  76. SOURIANARAYANANE A, Brydges CR, McCullough AJ
    Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity.
    Clin Res Hepatol Gastroenterol. 2024;48:102402.
    PubMed     Abstract available


  77. DING W, Xi S, Gao K, Weng D, et al
    Clinical significance of LINC02532 in hepatitis B virus-associated hepatocellular carcinoma and its regulatory effect on tumor progression.
    Clin Res Hepatol Gastroenterol. 2024;48:102403.
    PubMed     Abstract available


  78. PRIEGO-PARRA BA, Reyes-Diaz SA, Ordaz-Alvarez HR, Bernal-Reyes R, et al
    Diagnostic performance of sixteen biomarkers for MASLD: A study in a Mexican cohort.
    Clin Res Hepatol Gastroenterol. 2024;48:102400.
    PubMed     Abstract available


  79. WU J, Chen X, Qian J, Li G, et al
    Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2024;48:102397.
    PubMed     Abstract available


  80. LI R, Lee S, Rienas W, Sarin S, et al
    Higher risk of in-hospital mortality and hepatic encephalopathy during weekend admission in Transjugular Intrahepatic Portosystemic Shunt procedure.
    Clin Res Hepatol Gastroenterol. 2024;48:102396.
    PubMed     Abstract available


  81. JIANG R, Hua Y, Hu X, Hong Z, et al
    The pan immune inflammatory value in relation to non-alcoholic fatty liver disease and hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2024;48:102393.
    PubMed     Abstract available


  82. HU J, Mi Y, Wang L, Jiang F, et al
    Exploring the role of mitochondrial proteins SIRT5 and MRPL33 through Mendelian randomization in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102394.
    PubMed     Abstract available


  83. RASHU EB, Werge MP, Hetland LE, Thing M, et al
    Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
    Clin Res Hepatol Gastroenterol. 2024;48:102389.
    PubMed     Abstract available


  84. WANG J, Xiao P, Li X, Wu W, et al
    Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102390.
    PubMed     Abstract available


  85. KONG X, Fan Z, Li R, Hu D, et al
    Endoscopic ultrasound-guided fine-needle aspiration in the diagnostic value of focal liver lesions: A systematic analysis of 88 cases (with video).
    Clin Res Hepatol Gastroenterol. 2024;48:102382.
    PubMed     Abstract available


  86. NI K, Meng L
    Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102381.
    PubMed     Abstract available


  87. LIM WX, Yeh WS, Lee SY, Chuang YH, et al
    Psoas muscle area as a predictor of low muscle mass in Asian patients with compensated advanced chronic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102379.
    PubMed     Abstract available


  88. ALSHEHADE SA
    Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics.
    Clin Res Hepatol Gastroenterol. 2024;48:102377.
    PubMed     Abstract available


    July 2024
  89. BALE G, Clarembeau F, Starkel P, Dahlqvist G, et al
    Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Jul 22:102428.
    PubMed     Abstract available


    June 2024
  90. L'HUILLIER R, Michoud C, Dumortier J, Milot L, et al
    Massive peritoneal tumoral dissemination after hepatocellular carcinoma percutaneous microwave ablation with intraperitoneal CO(2) insufflation.
    Clin Res Hepatol Gastroenterol. 2024;48:102376.
    PubMed    


  91. ROGALSKI J, Czarnecka-Chrebelska K, Weglewska K, Pleska K, et al
    Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients.
    Clin Res Hepatol Gastroenterol. 2024;48:102366.
    PubMed    


  92. ZHOU J, Liang T, Xing F, Li X, et al
    Probabilistic Scatter Plots for visualizing carbohydrate and lipid metabolism states in Non-Alcoholic Fatty Liver Disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102365.
    PubMed     Abstract available


  93. ZHAO G, Shi R, Ma M, Lin H, et al
    Elevated LDL-c may warn of the risk of gallbladder stones in the patients with metabolic dysfunction-associated steatotic liver disease: A case-control study.
    Clin Res Hepatol Gastroenterol. 2024;48:102363.
    PubMed     Abstract available


  94. MAREY MM, Belal M, Awad AA, Rabea EM, et al
    Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2024;48:102357.
    PubMed     Abstract available


  95. LEIDECK P, Nkontchou G, Elkrief L, Erard D, et al
    The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience.
    Clin Res Hepatol Gastroenterol. 2024;48:102355.
    PubMed     Abstract available


  96. TANAKA A, Corpechot C
    PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old.
    Clin Res Hepatol Gastroenterol. 2024;48:102358.
    PubMed     Abstract available


  97. ZHOU F, Liu X, Chang C, Liu J, et al
    Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102352.
    PubMed     Abstract available


  98. BOEKEN T
    Redefining challenging liver thermal ablation cases: Present realities, future prospects.
    Clin Res Hepatol Gastroenterol. 2024;48:102342.
    PubMed    


  99. MENG X, Wang L, Du YC, Cheng D, et al
    PPARbeta/delta as a promising molecular drug target for liver diseases: A focused review.
    Clin Res Hepatol Gastroenterol. 2024;48:102343.
    PubMed     Abstract available


  100. PAN X, Hu E, Zhou Y, Li L, et al
    The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102344.
    PubMed     Abstract available


    May 2024
  101. MANSUR A, Grobman B, Lu CY
    Suicide risk is elevated among patients with chronic liver disease and cirrhosis in the United States.
    Clin Res Hepatol Gastroenterol. 2024;48:102378.
    PubMed    


  102. ZHU X, Zeng C, Yu B
    White adipose tissue in metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102336.
    PubMed     Abstract available


  103. ABBASSI N, Bourrahouat A, Bedoya EC, Pagan C, et al
    Phenotype and molecular characterization of Wilson's disease in Morocco.
    Clin Res Hepatol Gastroenterol. 2024;48:102335.
    PubMed     Abstract available


  104. WONG SH, Ng HI, Liu Y, Yu HH, et al
    Endoscopic submucosal dissection for early esophageal squamous cell carcinoma after ligation and sclerotherapy of esophageal and gastric varices.
    Clin Res Hepatol Gastroenterol. 2024;48:102339.
    PubMed     Abstract available


  105. FULBERT M, El Amrani M, Baillet C, Lecolle K, et al
    Sarcopenia does not affect liver regeneration and postoperative course after a major hepatectomy. A prospective study on 125 patients using CT volumetry and HIDA scintigraphy.
    Clin Res Hepatol Gastroenterol. 2024;48:102332.
    PubMed     Abstract available


  106. LI R, Sarin S
    The smoker's paradox in transjugular intrahepatic portosystemic shunt procedure: A national inpatient sample analysis from 2015 to 2020.
    Clin Res Hepatol Gastroenterol. 2024;48:102323.
    PubMed     Abstract available


  107. LIANG Y, Li J, Zhang Z, Jiang T, et al
    Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk.
    Clin Res Hepatol Gastroenterol. 2024;48:102321.
    PubMed     Abstract available


  108. CHANG G, Sun J, Li J, Li T, et al
    Effect of Probiotics on Portal Hypertension (PH) with Cirrhosis: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2024 May 1:102361.
    PubMed     Abstract available


    April 2024
  109. PATEL K, Twohig P, Peeraphatdit T, Stohs EJ, et al
    Outcomes and factors associated with cryptococcal disease among cirrhotics: A study of the national inpatient sample 2005 to 2014.
    Clin Res Hepatol Gastroenterol. 2024;48:102337.
    PubMed     Abstract available


  110. LI Y, Guo Y, Tan S
    Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102320.
    PubMed     Abstract available


  111. ORUC M, Gedik ME, Uner M, Ulug E, et al
    Effectiveness of metformin for the reversal of cold-ischemia-induced damage in hepatosteatosis.
    Clin Res Hepatol Gastroenterol. 2024;48:102314.
    PubMed     Abstract available


  112. JI J, Zhang Z, Hou Z, Qiu G, et al
    Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102313.
    PubMed     Abstract available


    March 2024
  113. NDHLOVU E, Zhang BX, Chen XP, Zhu P, et al
    Thermal ablation for hepatic tumors in high-risk locations.
    Clin Res Hepatol Gastroenterol. 2024;48:102300.
    PubMed     Abstract available


  114. LI B, Ren ZW, Zhang C, Yu XX, et al
    Computed tomography-guided percutaneous cryoablation and microwave ablation in the treatment of perivascular hepatocellular carcinoma: A comparative study with propensity score matching.
    Clin Res Hepatol Gastroenterol. 2024;48:102298.
    PubMed     Abstract available


  115. RAN D, Xin C, Ma Y, Lu Y, et al
    Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components.
    Clin Res Hepatol Gastroenterol. 2024;48:102302.
    PubMed     Abstract available


  116. CHEN F, Chen C, Zhang Y, Jiang L, et al
    Bilateral optic atrophy in Wilson disease: A case report and literature review.
    Clin Res Hepatol Gastroenterol. 2024;48:102299.
    PubMed     Abstract available


  117. AN Y, Xia Y, Wang Z, Jin GZ, et al
    Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102289.
    PubMed     Abstract available


  118. HAYAT HMS, Naeem H
    Aspirin for non alcoholic fatty liver disease: Promising but inconclusive-A letter to the editor.
    Clin Res Hepatol Gastroenterol. 2024;48:102286.
    PubMed    


  119. HOOSHMAND GHARABAGH L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A, et al
    Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102279.
    PubMed     Abstract available


    February 2024
  120. GUO J, Shi L, Sun Y
    Association of composite dietary antioxidant index and muscle mass in individuals with metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102284.
    PubMed     Abstract available


  121. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    PubMed     Abstract available


  122. MEJAIT A, Roux C, Soret M, Larrey E, et al
    Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
    Clin Res Hepatol Gastroenterol. 2024;48:102282.
    PubMed     Abstract available


  123. QI X, Liu L
    The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological features.
    Clin Res Hepatol Gastroenterol. 2024;48:102273.
    PubMed     Abstract available


  124. XIE C, Liu K, Xie Y, Liu S, et al
    Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102264.
    PubMed     Abstract available


  125. OBADIA MA, Woimant F, Tuppin P, Debray D, et al
    Reply to "Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the National health insurance database".
    Clin Res Hepatol Gastroenterol. 2024;48:102265.
    PubMed    


    January 2024
  126. KUMAR J, Mohsin S, Hasan M, Bilal AR, et al
    Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102261.
    PubMed     Abstract available


  127. KUMAR MS
    Paneth cell: The missing link between obesity, MASH and portal hypertension.
    Clin Res Hepatol Gastroenterol. 2024;48:102259.
    PubMed     Abstract available


  128. BAEK KW, Won JH, Xiang YY, Woo DK, et al
    Exercise intensity impacts the improvement of metabolic dysfunction-associated steatotic liver disease via variations of monoacylglycerol O-acyltransferase 1 expression.
    Clin Res Hepatol Gastroenterol. 2024;48:102263.
    PubMed     Abstract available


  129. CHEVAL M, Latrasse M, Tran Ba S, Robbe G, et al
    Extensive cortical and thalamic FLAIR hypersignals in a patient with suspected hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2024;48:102258.
    PubMed    


  130. SEXTON F, Shanahan W, Ryan JD
    Xanthoma striatum palmare: Getting a handle on hyperlipidaemia in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102255.
    PubMed    


    December 2023
  131. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    PubMed     Abstract available


  132. LASSAILLY G, Ningarhari M, Dumortier J, Lafforgue C, et al
    Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;48:102266.
    PubMed     Abstract available


  133. JIANG J, Hu Y, Fang D, Luo J, et al
    Glutamine synthetase and hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102248.
    PubMed     Abstract available


  134. ZHANG X, Li X, Xiong X
    Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Clin Res Hepatol Gastroenterol. 2023;47:102230.
    PubMed     Abstract available


  135. JANG H, Han N, Staatz CE, Kwak JH, et al
    Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102227.
    PubMed     Abstract available


  136. TAMILMANI P, Sathibabu Uddandrao VV, Chandrasekaran P, Saravanan G, et al
    Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-alpha/AMPK and Nrf-2/HO-1 signaling pathways.
    Clin Res Hepatol Gastroenterol. 2023;47:102231.
    PubMed     Abstract available


  137. PEI E, Wang H, Li Z, Xie X, et al
    Endoplasmic reticulum stress inhibitor may substitute for sleeve gastrectomy to alleviate metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102229.
    PubMed     Abstract available


  138. JIANG R, Zhou Y, Han L, Hong Z, et al
    Serum vitamin D is associated with ultrasound-defined hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2023;47:102228.
    PubMed     Abstract available


  139. DONATI A, Henrion J, Regnier M, Deltenre P, et al
    Abstinence is associated with better outcomes in patients with alcohol-related hepatocellular carcinoma: Results of an observational study.
    Clin Res Hepatol Gastroenterol. 2023;47:102225.
    PubMed     Abstract available


    November 2023
  140. ALLAIRE M, Roux C, Akhavan S, Lebray P, et al
    Difficulties in assessing portal hypertension in case of HVB-HVD co infection.
    Clin Res Hepatol Gastroenterol. 2023;47:102213.
    PubMed    


  141. MUTANEN A, Pakarinen MP
    Featuring molecular regulation of bile acid homeostasis in pediatric short bowel syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102220.
    PubMed     Abstract available


    October 2023
  142. DENG K, Yang F, Liu X, Deng M, et al
    Adult Kasabach-Merritt syndrome secondary to hepatic angiosarcoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102211.
    PubMed    


  143. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    PubMed     Abstract available


  144. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    PubMed     Abstract available


  145. DI GIORGIO A, Sciveres M, Fuoti M, Sonzogni A, et al
    Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.
    Clin Res Hepatol Gastroenterol. 2023;47:102185.
    PubMed     Abstract available


  146. BOILLOT O, Guillaud O, Wischlen E, Ruiz M, et al
    Determinants of early surgical complications after pediatric liver transplantation: A single center/single surgeon experience over 20 years.
    Clin Res Hepatol Gastroenterol. 2023;47:102222.
    PubMed     Abstract available


    August 2023
  147. XU J, Shao R, Zhang X, Yao D, et al
    Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
    Clin Res Hepatol Gastroenterol. 2023;47:102149.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.